Replies to post #133394 on Biotech Values

[DewDiligence]

…hopefully MNTA will ultimately land a much more lucrative deal than WPI.

WPI isn’t offering AMGN any technology, but rather money (up to $400M) and marketing expertise. Hence, what WPI got from AMGN is fundamentally different from what MNTA expects to get from a prospective FoB partner.

[DewDiligence]

…AMGN not being on board with MNTA's more aggressive approach in trying to develop fully-interchangeable biologics and not just biosimilars?

The AMGN-WPI partnership is clearly focused—at least initially—on non-substitutable FoB’s using the traditional BLA pathway. According to Paul Bisaro (WPI’s CEO), the partnership might eventually move into substitutable FoB’s for the US market.

Is it a bad sign [for MNTA]?

Yes, in the sense that there is one fewer prospective FoB partner; however, AMGN was not on my list of likely partners in the first place (#msg-69341004).